Phase III Results Bode Well For Merck Migraine Therapy Telcagepant
This article was originally published in The Pink Sheet Daily
Investigational drug compares in efficacy to AstraZeneca's Zomig, with fewer side effects, Merck says.
You may also be interested in...
Potential hurdles for Pozen-partnered migraine combo drug include BiDil-like woes and switchover problems.
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.